Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study

被引：86

作者：

Hu, Jiao ^{[1
,2
]}

Chen, Jinbo ^{[1
,2
]}

Ou, Zhenyu ^{[1
,2
,4
]}

Chen, Haige ^{[3
]}

Liu, Zheng

Chen, Minfeng ^{[1
,2
]}

Zhang, Ruiyun ^{[3
]}

Yu, Anze ^{[5
]}

Cao, Rui ^{[6
]}

Zhang, Enchong ^{[7
]}

Guo, Xi ^{[8
]}

Peng, Bo ^{[9
]}

Deng, Dingshan ^{[1
,2
]}

Cheng, Chunliang ^{[1
,2
]}

Liu, Jinhui ^{[1
,2
]}

Li, Huihuang ^{[1
,2
]}

Zou, Yihua ^{[10
]}

Deng, Ruoping ^{[11
]}

Qin, Gang ^{[11
]}

Li, Wenze

Wang, Lue ^{[12
,13
]}

Chen, Tao ^{[14
]}

Pei, Xiaming ^{[15
]}

Gong, Guanghui ^{[16
]}

Tang, Jiansheng ^{[17
]}

Othmane, Belaydi ^{[1
,2
]}

Cai, Zhiyong ^{[1
,2
]}

Zhang, Chunyu ^{[1
,2
]}

Liu, Zhi ^{[1
,2
]}

Zu, Xiongbing ^{[1
,2
]}

机构：

[1] Cent South Univ, Xiangya Hosp, Dept Urol, Changsha, Peoples R China

[2] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China

[3] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China

[4] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Urol, Wuhan, Peoples R China

[5] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Peoples R China

[6] Capital Med Univ, Beijing Friendship Hosp, Dept Urol, Beijing, Peoples R China

[7] China Med Univ, Shengjing Hosp, Dept Urol, Shenyang, Peoples R China

[8] Hunan Normal Univ, Hunan Prov Peoples Hosp, Affiliated Hosp 1, Dept Urol, Changsha, Peoples R China

[9] Zhangjiajie Peoples Hosp, Dept Urol, Zhangjiajie, Peoples R China

[10] First Peoples Hosp Chenzhou, Dept Urol, Chenzhou, Peoples R China

[11] Cent Hosp Yongzhou, Dept Urol, Yongzhou, Peoples R China

[12] First Peoples Hosp Xiangtan City, Dept Urol, Xiangtan, Peoples R China

[13] Huarong Peoples Hosp, Dept Urol, Yueyang, Peoples R China

[14] Xiangyang Cent Hosp, Dept Urol, Xiangyang, Peoples R China

[15] Hunan Canc Hosp, Dept Urol, Changsha, Peoples R China

[16] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha, Peoples R China

[17] Xiangnan Univ, Affiliated Hosp, Dept Urol, Chenzhou, Peoples R China

来源：

CELL REPORTS MEDICINE | 2022年 / 3卷 / 11期

基金：

中国国家自然科学基金; 湖南省自然科学基金;

关键词：

PHASE-III TRIAL; UROTHELIAL CARCINOMA; TUMOR MICROENVIRONMENT; OPEN-LABEL; END-POINT; PEMBROLIZUMAB; CISPLATIN; OUTCOMES; TISLELIZUMAB; ATEZOLIZUMAB;

D O I：

10.1016/j.xcrm.2022.100785

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab), neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination therapy (tislelizumab + GC) in patients with mus-cle-invasive bladder cancer (MIBC) and explore the efficacy predictors, we perform a multi-center, real-world cohort study that enrolls 253 patients treated with neoadjuvant treatments (combination therapy: 98, chemo-therapy: 107, and immunotherapy: 48) from 15 tertiary hospitals. We demonstrate that neoadjuvant combi-nation therapy achieves the highest complete response rate and pathological downstaging rate compared with neoadjuvant immunotherapy or chemotherapy. We develop and validate an efficacy prediction model consisting of pretreatment clinical characteristics, which can pinpoint candidates to receive neoadjuvant combination therapy. We also preliminarily reveal that patients who achieve pathological complete response after neoadjuvant treatments plus maximal transurethral resection of the bladder tumor may be safe to receive bladder preservation therapy. Overall, this study highlights the benefit of neoadjuvant combination therapy based on tislelizumab for MIBC.

引用

页数：17

共 50 条

[21] Neoadjuvant Chemotherapy Prior to Radical Cystectomy for Muscle-Invasive Bladder Cancer With Variant Histology [J].

Vetterlein, Malte W. ;

Wankowicz, Stephanie A. M. ;

Seisen, Thomas ;

Lander, Richard ;

Loppenberg, Bjorn ;

Chun, Felix K. -H. ;

Menon, Mani ;

Sun, Maxine ;

Barletta, Justine A. ;

Choueiri, Toni K. ;

Bellmunt, Joaquim ;

Quoc-Dien Trinh ;

Preston, Mark A. .

CANCER, 2017, 123 (22) :4346-4355

[22] Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer [J].

Zargar, Homayoun ;

Espiritu, Patrick N. ;

Fairey, Adrian S. ;

Mertens, Laura S. ;

Dinney, Colin P. ;

Mir, Maria C. ;

Krabbe, Laura-Maria ;

Cookson, Michael S. ;

Jacobsen, Niels-Erik ;

Gandhi, Nilay M. ;

Griffin, Joshua ;

Montgomery, Jeffrey S. ;

Vasdev, Nikhil ;

Yu, Evan Y. ;

Youssef, David ;

Xylinas, Evanguelos ;

Campain, Nicholas J. ;

Kassouf, Wassim ;

Dall'Era, Marc A. ;

Seah, Jo-An ;

Ercole, Cesar E. ;

Horenblas, Simon ;

Sridhar, Srikala S. ;

McGrath, John S. ;

Aning, Jonathan ;

Shariat, Shahrokh F. ;

Wright, Jonathan L. ;

Thorpe, Andrew C. ;

Morgan, Todd M. ;

Holzbeierlein, Jeff M. ;

Bivalacqua, Trinity J. ;

North, Scott ;

Barocas, Daniel A. ;

Lotan, Yair ;

Garcia, Jorge A. ;

Stephenson, Andrew J. ;

Shah, Jay B. ;

van Rhijn, Bas W. ;

Daneshmand, Siamak ;

Spiess, Philippe E. ;

Black, Peter C. .

EUROPEAN UROLOGY, 2015, 67 (02) :241-249

[23] Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer [J].

Macleod, Liam C. ;

Fam, Mina M. ;

Yabes, Jonathan G. ;

Hale, Nathan E. ;

Turner, Robert M., II ;

Lopa, Samia H. ;

Gingrich, Jeffrey R. ;

Borza, Tudor ;

Skolarus, Ted A. ;

Davies, Benjamin J. ;

Jacobs, Bruce L. .

CLINICAL GENITOURINARY CANCER, 2020, 18 (03) :201-+

[24] Immunotherapy in neoadjuvant setting in muscle-invasive bladder cancer, what's new? [J].

Alkassis, Marwan ;

Sarkis, Julien ;

Tayeh, Georges Abi ;

Kourie, Hampig Raphael ;

Nemer, Elie .

IMMUNOTHERAPY, 2021, 13 (06) :459-463

[25] Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer [J].

Ajib, Khaled ;

Tjong, Michael C. ;

Tan, Guan Hee ;

Nason, Gregory ;

Berjaoui, Mohammad Baker ;

Erlich, Annette ;

Maganti, Manjula ;

Sridhar, Srikala ;

Fleshner, Neil E. ;

Zlotta, Alexandre R. ;

Catton, Charles ;

Berlin, Alejandro ;

Chung, Peter ;

Kulkarni, Girish S. .

CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2020, 14 (12) :404-410

[26] Efficacy and safety analysis of neoadjuvant chemotherapy combined with immunotherapy in patients with muscle-invasive bladder cancer [J].

Yu, Yanhang ;

Zhang, Chuanao ;

Chen, Hao ;

Zhang, Jianglei ;

Ouyang, Jun ;

Zhang, Zhiyu .

FRONTIERS IN IMMUNOLOGY, 2024, 15

[27] Neoadjuvant chemotherapy for muscle-invasive bladder cancer: does variant histology matter? [J].

Catarino, Raquel ;

Alves, Luisa ;

Pereira, Diogo ;

Costa, Gabriel ;

Pereira, Joao ;

Cardoso, Andre ;

Braga, Isaac ;

Freitas, Rui ;

Correia, Tiago ;

Cerqueira, Manuel ;

Reis, Frederico Carmo ;

Lobo, Francisco ;

Silva, Vitor ;

Magalhaes, Sanches ;

Morais, Antonio ;

Prisco, Rui .

INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (12) :3163-3169

[28] Neoadjuvant chemotherapy for muscle-invasive bladder cancer with variant histology and/or divergent differentiation [J].

Tashiro, Kojiro ;

Urabe, Fumihiko ;

Kimura, Takahiro .

TRANSLATIONAL ANDROLOGY AND UROLOGY, 2025, 14 (05) :1155-1157

[29] Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit? [J].

Niegisch, Guenter ;

Lorch, Anja ;

Droller, Michael J. ;

Lavery, Hugh J. ;

Stensland, Kristian D. ;

Albers, Peter .

EUROPEAN UROLOGY, 2013, 64 (03) :355-357

[30] Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions [J].

Porras, Vicenc Ruiz de ;

Pardo, Juan Carlos ;

Etxaniz, Olatz ;

Font, Albert .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 178

← 1 2 3 4 5 →